Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures

Bibliography

• World Health Organization. Epilepsy Fact Sheet No 999. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/index.html [Last accessed 29 March 2012]
   Google Scholar
• Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6:793-804
   PubMed Web of Science ®Google Scholar
• French JA. Refractory epilepsy: clinical overview. Epilepsia 2007;48(Suppl 1):3-7
   PubMed Web of Science ®Google Scholar
• Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res 2002;50:21-32
   PubMed Web of Science ®Google Scholar
• Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001;56:1772-4
   PubMed Web of Science ®Google Scholar
• Lhatoo SD, Wong IC, Polizzi G, Sander JW. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000;41:1592-6
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 137. Available from: http://www.nice.org.uk/nicemedia/live/13635/57779/57779.pdf [Last accessed 31 July 2012]
   Google Scholar
• Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011;10:446-56
   PubMed Web of Science ®Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9:68-82
   PubMed Web of Science ®Google Scholar
• Chappell AS, Sander JW, Brodie MJ, A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;58:1680-2
   PubMed Web of Science ®Google Scholar
• Langan YM, Lucas R, Jewell H, Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 2003;44:46-53
   PubMed Web of Science ®Google Scholar
• Hanada T, Hashizume Y, Tokuhara N, Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-40
   PubMed Web of Science ®Google Scholar
• Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia 2009;50(Suppl 11):abstract 1.199
   Google Scholar
• Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11:56-63
   PubMed Web of Science ®Google Scholar
• Tokuhara N, Hatakeyama S, Amino H, Pharmacological profile of perampanel: a novel, non-competitive selective AMPA receptor antagonist. Abstract P02.112 presented at the 60th Annual Meeting of the American Academy of Neurology; 12 – 19 April 2008; Chicago, IL, USA
   Google Scholar
• Ceolin L, Bortolotto Z, Bannister N, A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 2012;61:517-22
   PubMed Web of Science ®Google Scholar
• Balannik V, Menniti FS, Paternain AV, Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron 2005;48:279-88
   Google Scholar
• Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 2009;462:745-56
   PubMed Web of Science ®Google Scholar
• Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47:217-27
   PubMed Web of Science ®Google Scholar
• Fuseau E, Templeton D, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr 2011;11(Suppl 1):abstract 1.264
   Google Scholar
• Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr 2012;12(Suppl 1):abstract 2.231
   Google Scholar
• Krauss GL, Bar M, Biton V, Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
   PubMed Web of Science ®Google Scholar
• French J, Krauss GL, Biton V, Adjunctive perampanel for refractory partial-onset seizures: randomized Phase III study 304. Neurology 2012;79:589-96
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Kramer L, Perucca E, Ben-Menachem E, Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: a dose-response analysis from Phase III studies. Neurology 2012;78(Suppl 1):abstract P06.117
   Google Scholar
• Rektor I, Krauss GL, Bar M, Perampanel study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:263-9
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III extension study 307. Epilepsia 2012; Epub ahead of print
   Google Scholar
• St Louis EK. Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care. Curr Neuropharmacol 2009;7:106-14
   Google Scholar
• French J, Elger C, Goldberg-Stern H, Use of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: results of a global phase III study. Abstract 020 presented at the 29th International Epilepsy Congress; 1 September – 28 August 2011; Rome, Italy
   Google Scholar
• Hussein Z, Ferry J, Krauss G.L, Demographic factors and concomitant antiepileptic drugs have no effects on the pharmacodynamics of perampanel. Poster presented at the 64th American Academy of Neurology Annual Meeting; 21 – 28 April 2012; New Orleans, LA, USA
   Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:18-61
   PubMed Web of Science ®Google Scholar
• Lees GJ. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 2000;59:33-78
   PubMed Web of Science ®Google Scholar